Inventor · disambiguated record
Robert Kotin
Also filed as: KOTIN ROBERT · KOTIN ROBERT M · KOTIN ROBERT MICHAEL
26 granted patents·31 pending applications·1,278 citations·filing 1993–2025
97Inventor score
Files withVOYAGER THERAPEUTICS INC15GENERATION BIO CO13US HEALTH11SYNTENY THERAPEUTICS INC5UNIV MASSACHUSETTS3
Top patents by PatentIndex Score
57 records- 0198US6984517B1AAV5 vector and uses thereofUS HEALTH·Filed 2000·Granted Jan 10, 2006·125 cites·25 claims
- 0298US6468524B1AAV4 vector and uses thereofUS HEALTH·Filed 2000·Granted Oct 22, 2002·205 cites·12 claims
- 0397US8846389B2AAV4 vector and uses thereofUS HEALTH·Filed 2013·Granted Sep 30, 2014·48 cites·11 claims
- 0497US7479554B2AAV5 nucleic acidsUS HEALTH·Filed 2005·Granted Jan 20, 2009·64 cites·26 claims
- 0596US6855314B1AAV5 vector for transducing brain cells and lung cellsUS HEALTH·Filed 2000·Granted Feb 15, 2005·99 cites·9 claims
- 0695US6723551B2Production of adeno-associated virus in insect cellsUS HEALTH·Filed 2002·Granted Apr 20, 2004·263 cites·36 claims
- 0794US10335466B2AADC polynucleotides for the treatment of parkinson's diseaseVOYAGER THERAPEUTICS INC·Filed 2015·Granted Jul 2, 2019·11 cites·14 claims
- 0894US7271002B2Production of adeno-associated virus in insect cellsUS HEALTH·Filed 2002·Granted Sep 18, 2007·124 cites·52 claims
- 0993US7718424B2AAV4 vector and uses thereofUS HEALTH·Filed 2003·Granted May 18, 2010·27 cites·1 claims
- 1092US11027000B2AADC polynucleotides for the treatment of Parkinson's diseaseVOYAGER THERAPEUTICS INC·Filed 2019·Granted Jun 8, 2021·4 cites·26 claims
- 1192US9598703B2Capsid-free AAV vectors, compositions, and methods for vector production and gene deliveryGARCIA LUIS·Filed 2012·Granted Mar 21, 2017·48 cites·17 claims
- 1291US11066679B2Closed-ended linear duplex DNA for non-viral gene transferUNIV MASSACHUSETTS·Filed 2017·Granted Jul 20, 2021·10 cites·16 claims
- 1391US10577627B2Chimeric capsidsVOYAGER THERAPEUTICS INC·Filed 2015·Granted Mar 3, 2020·6 cites·28 claims
- 1489US8507267B2AAV4 vector and uses thereofCHIORINI JOHN A·Filed 2010·Granted Aug 13, 2013·7 cites·35 claims
- 1588US2024415943A1Aadc polynucleotides for the treatment of parkinson's diseaseVOYAGER THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1687US6821511B2Methods of using adeno-associated virus rep proteinUS HEALTH·Filed 2001·Granted Nov 23, 2004·29 cites·4 claims
- 1787US5693531AVector systems for the generation of adeno-associated virus particlesUS ARMY·Filed 1993·Granted Dec 2, 1997·140 cites·6 claims
- 1879US2025000071A1Identifying and characterizing genomic safe harbors (gsh) in humans and murine genomes, and viral and non-viral vector compositions for targeted integration at an identified gsh lociGENERATION BIO CO·Filed 2024·Application pending·0 cites
- 1977US11975056B2AADC polynucleotides for the treatment of Parkinson's diseaseVOYAGER THERAPEUTICS INC·Filed 2021·Granted May 7, 2024·0 cites·24 claims
- 2072US2023159953A1Closed-ended, linear, duplex adenoassociated virus dna, and uses thereofUS HEALTH·Filed 2023·Application pending·0 cites
- 2171US12252703B2Closed-ended linear duplex DNA for non-viral gene transferUNIV MASSACHUSETTS·Filed 2021·Granted Mar 18, 2025·0 cites·20 claims
- 2271US6342390B1Lipid vesicles containing adeno-associated virus rep protein for transgene integration and gene therapyUS HEALTH·Filed 1994·Granted Jan 29, 2002·36 cites·18 claims
- 2371US5580703AHuman adeno-associated virus integration site DNA and uses thereofAMERICAN CYANAMID CO·Filed 1994·Granted Dec 3, 1996·32 cites·8 claims
- 2470US2014348794A1Aav4 vector and uses thereofUSA AS REPRESENTED BY THE SECRETARY DEPT OF HEALTH AND HUMAN SERVICES·Filed 2014·Application pending·0 cites
- 2570US2019008933A1Aadc polynucleotides for the treatment of parkinson's diseaseVOYAGER THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 2670US2019008931A1Aadc polynucleotides for the treatment of parkinson's diseaseVOYAGER THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 2770US2019008932A1Aadc polynucleotides for the treatment of parkinson's diseaseVOYAGER THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 2869US2025320521A1Erythroparvovirus compositions and methods for gene therapySYNTENY THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2969US2022195459A1Regulatable expression using adeno-associated virus (aav)VOYAGER THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3069US2025302994A1Erythroparvovirus with a modified genome for gene therapySYNTENY THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3169US2025295810A1Erythroparvovirus with a modified capsid for gene therapySYNTENY THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3268US2025290094A1Closed-ended linear duplex dna for non-viral gene transferUNIV MASSACHUSETTS·Filed 2025·Application pending·0 cites
- 3367US12180500B2Chimeric capsidsVOYAGER THERAPEUTICS INC·Filed 2020·Granted Dec 31, 2024·0 cites·10 claims
- 3462US11549125B2Closed-ended, linear, duplex adenoassociated virus DNA, and uses thereofTHE USA AS REPRESENTED BY THE SECRETARY DEPT OF HEALTH AND HUMAN SERVICES·Filed 2017·Granted Jan 10, 2023·0 cites·23 claims
- 3561US2025087304A1Genomic safe harborsSYNTENY THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3660US12383615B2Protoparvovirus compositions comprising a protoparvovirus variant VP1 capsid polypeptide and related methodsCARBON BIOSCIENCES INC·Filed 2024·Granted Aug 12, 2025·0 cites·21 claims
- 3759US2019054158A1Compositions and methods for the treatment of aadc deficiencyVOYAGER THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3859US2020390072A1Identifying and characterizing genomic safe harbors (gsh) in humans and murine genomes, and viral and non-viral vector compositions for targeted integration at an identified gsh lociGENERATION BIO CO·Filed 2019·Application pending·0 cites
- 3959US2024066080A1Protoparvovirus and tetraparvovirus compositions and methods for gene therapySYNTENY THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4052US2019000940A1Compositions and methods for the treatment of aadc deficiencyVOYAGER THERAPEUTICS INC·Filed 2016·Application pending·0 cites
- 4152US2022127625A1Modulation of rep protein activity in closed-ended dna (cedna) productionGENERATION BIO CO·Filed 2020·Application pending·0 cites
- 4251US2023049217A1Compositions and methods for enhancing visual functionNOVARTIS AG·Filed 2022·Application pending·0 cites
- 4351US2018230489A1Regulatable expression using adeno-associated virus (aav)VOYAGER THERAPEUTICS INC·Filed 2016·Application pending·0 cites
- 4450US10882886B2Adeno-associated virus polynucleotides, polypeptides and virionsCHILDRENS MEDICAL RES INSTITUTE·Filed 2017·Granted Jan 5, 2021·0 cites·21 claims
- 4549US2021054405A1Closed-ended dna (cedna) vectors for insertion of transgenes at genomic safe harbors (gsh) in humans and murine genomesGENERATION BIO CO·Filed 2019·Application pending·0 cites
- 4649US2021388379A1Modified closed-ended dna (cedna) comprising symmetrical modified inverted terminal repeatsGENERATION BIO CO·Filed 2019·Application pending·0 cites
- 4748US2022119840A1Closed-ended dna (cedna) and use in methods of reducing gene or nucleic acid therapy related immune responseGENERATION BIO CO·Filed 2020·Application pending·0 cites
- 4846US2022228171A1Compositions and production of nicked closed-ended dna vectorsGENERATION BIO CO·Filed 2020·Application pending·0 cites
- 4944US2021059953A1Lipid nanoparticle formulations of non-viral, capsid-free dna vectorsGENERATION BIO CO·Filed 2018·Application pending·0 cites
- 5042US12442015B2Closed-ended DNA vectors obtainable from cell-free synthesis and process for obtaining ceDNA vectorsGENERATION BIO CO·Filed 2019·Granted Oct 14, 2025·0 cites·16 claims
Showing the top 50 of 57 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →